Form 4: Protara Therapeutics CEO Gifts Over 18,000 Shares of Common Stock Under 10b5-1 Plan

Protara Therapeutics, Inc. CEO and President Jesse Shefferman reported the disposition of 18,667 shares of common stock as bona fide gifts under a Rule 10b5-1 plan.

Summary

• Jesse Shefferman, who serves as CEO, President, Director, and a 10% Owner of Protara Therapeutics, Inc. (TARA), reported changes in his beneficial ownership.
• He disposed of a total of 18,667 shares of Protara Therapeutics common stock.
• The dispositions occurred on June 26, 2025 (1,700 shares and 3,400 shares) and June 27, 2025 (10,200 shares and 3,367 shares).
• The transactions were coded as 'G,' indicating bona fide gifts, with a reported price of $0 per share.
• Following these transactions, Jesse Shefferman beneficially owns 959,886 shares of Protara Therapeutics common stock.
• The transactions were made pursuant to a Rule 10b5-1 plan, which allows insiders to set up pre-arranged trading plans to avoid accusations of trading on material non-public information.

Sentiment

Score: 6

Explanation: The disposition of shares by the CEO is noted, but the transactions are identified as bona fide gifts (Code G) and were conducted under a Rule 10b5-1 plan, which generally indicates pre-planned, non-discretionary transactions. This mitigates concerns that the insider is selling due to negative company prospects.

Positives

• The transactions were conducted under a Rule 10b5-1 plan, which can help mitigate concerns about insider trading by pre-scheduling transactions.
• The disposition was a gift, not a sale for cash, which means the insider is not liquidating shares for personal financial gain.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if a gift, reduces their direct stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is specific to Protara Therapeutics and does not directly reflect broader industry trends, though insider activity is always monitored by investors for sentiment.

Comparison to Industry Standards

• This document reports an insider transaction and does not provide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies or projects.

Stakeholder Impact

• Shareholders: The reduction in direct beneficial ownership by a key executive, even if a gift, may be noted by investors, though the nature of the transaction (gift, 10b5-1 plan) generally lessens negative interpretations compared to open market sales.

Key Dates

Recommendation

Keywords

Protara Therapeutics, TARA, Jesse Shefferman, Insider Trading, Form 4, Beneficial Ownership, Stock Disposition, Rule 10b5-1, Gift of Shares